日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies

伊曲康唑和利福平对细胞色素P450 3A抑制和诱导作用对晚期恶性肿瘤患者他泽美司他药代动力学的影响

期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.1543
Chen, Yingxue; Teng, Renli; Szanto, Attila; Kapopara, Apoorva; Bannerji, Rajat; Ogier, Julien; Mahalingam, Devalingam
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

复发/难治性 B 细胞非霍奇金淋巴瘤患者肿瘤内免疫细胞亚群的分子评估及其对 CD20×CD3 双特异性抗体 odronextamab 的潜在耐药机制

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.3
doi:10.1136/jitc-2023-008338
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Max S Topp, Rajat Bannerji, Johannes Duell, Ranjana H Advani, Dina M Flink, Aafia Chaudhry, Gavin Thurston, Srikanth R Ambati, Vladimir Ja
肿瘤
淋巴瘤
B细胞
发表日期：2024
文献求助 收藏

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

固定疗程伊布替尼联合维奈克拉一线治疗慢性淋巴细胞白血病：CAPTIVATE FD队列的主要分析

期刊:Blood
影响因子:23.1
doi:10.1182/blood.2021014488
Tam, Constantine S; Allan, John N; Siddiqi, Tanya; Kipps, Thomas J; Jacobs, Ryan; Opat, Stephen; Barr, Paul M; Tedeschi, Alessandra; Trentin, Livio; Bannerji, Rajat; Jackson, Sharon; Kuss, Bryone J; Moreno, Carol; Szafer-Glusman, Edith; Russell, Kristin; Zhou, Cathy; Ninomoto, Joi; Dean, James P; Wierda, William G; Ghia, Paolo
白血病
细胞生物学
发表日期：2022
文献求助 收藏

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Odronextamab，一种人源CD20×CD3双特异性抗体，用于治疗CD20阳性B细胞恶性肿瘤患者（ELM-1）：一项单臂、多中心I期试验中复发或难治性非霍奇金淋巴瘤队列的结果

期刊:Lancet Haematology
影响因子:17.7
doi:10.1016/S2352-3026(22)00072-2
Bannerji, Rajat; Arnason, Jon E; Advani, Ranjana H; Brown, Jennifer R; Allan, John N; Ansell, Stephen M; Barnes, Jeffrey A; O'Brien, Susan M; Chávez, Julio C; Duell, Johannes; Rosenwald, Andreas; Crombie, Jennifer L; Ufkin, Melanie; Li, Jingjin; Zhu, Min; Ambati, Srikanth R; Chaudhry, Aafia; Lowy, Israel; Topp, Max S
B细胞
肿瘤
肿瘤免疫
淋巴瘤
CD3
CD20
细胞生物学
CD2
免疫/内分泌
发表日期：2022
文献求助 收藏

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

慢性淋巴细胞白血病患者对伊布替尼完全缓解的预后因素：两项临床试验的汇总分析

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2017.5604
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C; Bannerji, Rajat; Blum, Kristie A; Fox, Christopher P; Furman, Richard R; Hillmen, Peter; Kipps, Thomas J; Montillo, Marco; Sharman, Jeff; Suzuki, Sam; James, Danelle F; Chu, Alvina D; Coutre, Steven E
白血病
细胞生物学
发表日期：2018
文献求助 收藏

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

一项针对晚期恶性肿瘤患者的I期安全性、药代动力学和药效学研究，评估每三周给药一次的细胞周期蛋白依赖性激酶抑制剂dinaciclib的疗效。

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2017.288
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L; Poon, Jennifer; Small, Karen A; Jou, Ying-Ming; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Statkevich, Paul; Sankhala, Kamelesh K; Sarantopoulos, John; Cleary, James M; Chirieac, Lucian R; Rodig, Scott J; Bannerji, Rajat; Shapiro, Geoffrey I
信号转导
细胞生物学
肿瘤
肿瘤免疫
发表日期：2017
文献求助 收藏

Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models

细胞周期蛋白依赖性激酶（Dinaciclib）和AKT（MK-2206）联合抑制可阻断患者来源异种移植模型中的胰腺肿瘤生长和转移

期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-15-0028
Hu, Chaoxin; Dadon, Tikva; Chenna, Venugopal; Yabuuchi, Shinichi; Bannerji, Rajat; Booher, Robert; Strack, Peter; Azad, Nilofer; Nelkin, Barry D; Maitra, Anirban
肿瘤
肿瘤免疫
信号转导
细胞生物学
AKT
发表日期：2015
文献求助 收藏

An unusual presentation of deltamethrin poisoning

溴氰菊酯中毒的一种不寻常表现

期刊:Indian Journal of Critical Care Medicine
影响因子:1.5
doi:10.4103/0972-5229.160305
Bala, Renu; Kaur, Navdeep; Bannerji, Arnab; Virmani, Rashmi
发表日期：2015
文献求助 收藏

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

一项首次人体试验的 I 期剂量递增研究，评估了新型细胞周期蛋白依赖性激酶抑制剂 dinaciclib 每周一次给药治疗晚期恶性肿瘤患者的疗效。

期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/1479-5876-11-259
Nemunaitis, John J; Small, Karen A; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Jou, Ying-Ming; Statkevich, Paul; Yao, Siu-Long; Bannerji, Rajat
信号转导
细胞生物学
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

新型细胞周期蛋白依赖性激酶抑制剂 dinaciclib (SCH 727965) 在急性白血病中的临床和实验室研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.7
doi:10.1007/s00280-013-2249-z
Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J Feldman, Swaminathan Padmanabhan Iyer, Maria R Baer, Edward A Sausville, Rena G Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji
肿瘤
白血病
其它细胞
发表日期：2013
文献求助 收藏